351327-32-7 Usage
Uses
Used in Pharmaceutical Industry:
6-Bromo-2-(4-chloro-phenyl)-quinoline-4-carboxylic acid is used as a building block in the synthesis of various pharmaceuticals. Its unique structure and potential biological activity make it a valuable component in the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
6-Bromo-2-(4-chloro-phenyl)-quinoline-4-carboxylic acid is also used as a building block in the synthesis of agrochemicals. Its antimicrobial properties can be harnessed to develop new pesticides or fungicides, contributing to the control of plant diseases and pests.
Used in Antimicrobial Applications:
6-Bromo-2-(4-chloro-phenyl)-quinoline-4-carboxylic acid is used as an antimicrobial agent due to its potential to inhibit the growth of various microorganisms. This property can be utilized in the development of new antibiotics or antifungal agents to combat drug-resistant infections.
Used in Antitumor Applications:
6-Bromo-2-(4-chloro-phenyl)-quinoline-4-carboxylic acid has been studied for its antitumor properties, making it a potential candidate for the development of new cancer therapies. Its ability to target and inhibit the growth of cancer cells can contribute to the advancement of oncology treatments.
Used in Anti-inflammatory Applications:
6-Bromo-2-(4-chloro-phenyl)-quinoline-4-carboxylic acid exhibits anti-inflammatory properties, which can be utilized in the development of new anti-inflammatory drugs. Its potential to reduce inflammation and alleviate pain can be beneficial in the treatment of various inflammatory conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 351327-32-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,3,2 and 7 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 351327-32:
(8*3)+(7*5)+(6*1)+(5*3)+(4*2)+(3*7)+(2*3)+(1*2)=117
117 % 10 = 7
So 351327-32-7 is a valid CAS Registry Number.
351327-32-7Relevant articles and documents
Discovery of novel tubulin inhibitors targeting the colchicine binding site via virtual screening, structural optimization and antitumor evaluation
Liu, Wei,Jia, Hairui,Guan, Minghao,Cui, Minxuan,Lan, Zhuxuan,He, Youyou,Guo, Zhongjie,Jiang, Ru,Dong, Guoqiang,Wang, Shengzheng
, (2021/11/22)
The colchicine binding site of tubulin is a promising target for discovering novel antitumor agents which exert the antiangiogenic effect and are not susceptible to multidrug resistance. For identifying novel tubulin inhibitors, structure-based virtual screening was applied to identify hit 9 which displayed moderate tubulin polymerization inhibition and broad-spectrum in vitro antitumor activity. Structural optimization was performed, and biological assay revealed analog E27 displayed the best antitumor activity with IC50 values ranging from 7.81 μM to 10.36 μM, and improved tubulin polymerization inhibitory activity (IC50 = 16.1 μM). It significantly inhibited cancer cell migration and invasion, induced cell apoptosis and arrested the cell cycle at G2/M phase. Moreover, the apoptotic effect of E27 is related to the increased ROS level, the decrease of MMP, and the abnormal expression of apoptosis-related proteins. Taken together, these results suggested E27 was a promising lead compound for discovering novel tubulin-targeted antitumor agents.
